

## **KAZIA THERAPEUTICS LIMITED**

### **VALUE STATEMENT**

February 2020

As a company working in human healthcare, and mindful of the trust accordingly vested in us by patients, physicians, and shareholders, Kazia places the utmost emphasis on ethical conduct in strict accordance with an inviolable set of principles and precepts. Our core values are as follows.

#### **PATIENT SAFETY**

Our foremost consideration must be for the safety and wellbeing of every patient who is treated with one of our products. No medicine can ever be entirely without risk, but we undertake to do everything possible to understand, quantify, explain, and manage the risks associated with our therapies. Should new information emerge, which changes the balance of risk associated with a Kazia product, we will act promptly and decisively to communicate and respond appropriately.

#### **DATA INTEGRITY**

The primary output of our company is scientific data, in all its forms and presentations, and it is imperative that clinicians, regulators, patients, and other stakeholders have absolute confidence and trust in our data. We take every opportunity to ensure that data is scientifically robust, accurately captured, properly analysed, and faithfully reported, in accordance with the highest standards of our industry.

#### **RESPONSIBLE CONDUCT**

We recognise that our company does not act in isolation, but as part of a broad network of scientists, physicians, industry professionals, and investors, whose commitment to us often exceeds the purely financial, and may encompass the image and reputation of our partners, and the trust and hope of sometimes vulnerable people. We undertake to always recognise these commitments, and to discharge ourselves in a manner that respects the rights, dignity, and best interests of all who interact with our company.

#### **SHAREHOLDER VALUE**

As a public company, we recognise and embrace our obligation to maximise shareholder value. Drug development is a high-risk industry, but we act always in a manner that minimises the risk of failure and maximises the opportunity for our work to bring benefit to patients. We believe that a commercially successful drug development company is invariably one that places patient need at the forefront of its work, and this conviction allays any potential tension between our commercial obligations and our commitment to high-quality science.